Xiao-en Xu
270 Dong An Road
Shanghai, 200032, China
Shanghai, 200032, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer.
Journal: Cancer research
Published: July 03, 2022
The early-stage triple-negative breast cancer landscape derives a novel prognostic signature and therapeutic target.
Journal: Breast cancer research and treatment
Published: November 03, 2021
MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer.
Journal: Journal for immunotherapy of cancer
Published: June 27, 2021
GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer.
Journal: Journal for immunotherapy of cancer
Published: May 30, 2021
Molecular Features and Functional Implications of Germline Variants in Triple-Negative Breast Cancer.
Journal: Journal of the National Cancer Institute
Published: March 16, 2020
eEF2 kinase mediated autophagy as a potential therapeutic target for paclitaxel-resistant triple-negative breast cancer.
Journal: Annals of translational medicine
Published: February 12, 2020
LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.
Journal: Molecular cancer
Published: December 02, 2019
Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
Journal: Cancer
Published: September 15, 2019
Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Journal: Theranostics
Published: August 11, 2018
The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation.
Journal: Science advances
Published: April 25, 2018
DSCAM-AS1 regulates the G1 /S cell cycle transition and is an independent prognostic factor of poor survival in luminal breast cancer patients treated with endocrine therapy.
Journal: Cancer medicine
Published: December 20, 2017
Last Updated: 09/26/2026